Important Message: Beware of Impersonation Scams

Fraudulent messages and advertisements are currently circulating on messaging platforms, including WhatsApp, impersonating Candriam’s brand and investment professionals. Please note that Candriam never offers investment recommendations or provides financial advice through social media channels or messaging platforms.

Monthly Coffee Break, Alternative Investments

The MOMOment of truth

April was dominated by the interaction between resilient global activity and a renewed energy shock linked to the Middle East conflict and impaired traffic through the Strait of Hormuz.
Monthly Coffee Break, Asset Allocation

Hormuz, we have a problem. Do we?

Bond markets are pricing the war in Iran. Equity markets are not. That divergence has become a defining feature in the past month. The conflict has now moved beyond the initial shock phase and has entered a regime of repeated escalation, partial de-escalation and unresolved disruption.
Monthly Coffee Break, Equities

Strong start to the earnings season rewarded by investors

European equities have experienced a slight contraction since the last Equity Committee in April, amid several macroeconomic headwinds. The collapse of Middle East ceasefire talks renewed geopolitical concerns and disrupted supply chains.
Research Paper, Fixed Income, Credit, Vincent Lapointe, Fabrice Sauzeau

Sustainable returns: in credit?

Why has the enthusiasm for sustainable investing lost its lustre? A lag in performance of sustainable European equities relative to the broader European equity markets over the last three years hasn’t helped. Sector rotation in equities is often blamed for this downturn in returns. .
Ken Van Weyenberg, Equities, ESG, SRI

A transition gaining speed

The environmental transition has entered a new phase. What was once seen as a gradual, policy-led shift is unfolding as a faster, economically driven transformation. Technology, cost dynamics and rising physical risks are converging, turning environmental change into a central force redefining growth, capital allocation and corporate strategy.
Linden Thomson, Sara Torrecilla, Healthcare

Biotechnology in 2026: innovation with selectivity

After a stronger 2025, biotechnology entered 2026 on firm footing. Innovation remains robust, valuations are still supportive and investor interest is improving. In a selective market, Candriam focuses on differentiated assets, commercial potential and disciplined portfolio construction.

Find it fast

Get information faster with a single click

Get insights straight to your inbox